MARKET UPDATES CONSUMER 🔸 $BSET: Q1 EPS $0.21 (est. $0.03), rev $82.2M (est. $79.62M). 🔸 $LCID: Q1 production 2,212 vehicles, 600+ in transit; delivered 3,109; files to sell $1B in notes; guides Q1 revs $232M-$236M (est. $256.3M). 🔸 $LYFT: Downgraded to Underperform at BofA, tgt cut to $10.50. 🔸 $NKE, $ADDYY: Shares drop on new 46% Vietnam tariff (impacting AEO, W). 🔸 $RH: Q4 revs $812.4M (est. $829.6M), EPS $1.58 (est. $1.91); guides FY25 rev growth 10%-13%; warns of tariff risks. 🔸 $ROST, $TJX: Upgraded to Buy at Citi; tariffs boost off-price retail inventory. ENERGY, INDUSTRIALS & MATERIALS 🔸 $BALL, $CCK: Potential impact from new 25% tariff on canned beer, aluminum. 🔸 $EMN: Upgraded to Outperform at Mizuho, tgt $105 (+18% upside). 🔸 $LSTR: Q1 EPS cut to $0.90-$0.95 (prior $1.05-$1.25) due to supply chain fraud. 🔸 $MSM: Q2 EPS $0.72 in line, revs $891.72M (est. $908.3M). 🔸 $PCAR: CFO Harrie Schippers to retire; Brice Poplawski promoted. FINANCIALS 🔸 $RGP: Q3 adj. EBITDA $1.7M (est. -$0.5M), revs $129.4M (est. $130M). HEALTHCARE 🔸 $RXST: Cuts FY25 rev view to $160M-$175M (prior $185M-$197M). 🔸 $SRNA: Files for $100M mixed shelf. 🔸 Drugmakers ($AZN, $SNY, $NVO): Spared from Trump tariffs, benefiting exporters. 🔸 Medical Devices ($DXCM, $GHHC, $BSX, $ABT): Under pressure due to new tariffs (34% China, 20% EU). TECH, MEDIA & TELECOM 🔸 $MSFT: Pausing data center projects, impacting VRT, CRWV, ETN, SMCI, DELL, VST, SMR, OKLO, NRG, CEG. 🔸 $GCT: Increases buyback by $16M. 🔸 $PDD: Investing $13B over three years to support merchants. 🔸 $PENG: Q2 EPS $0.52 (est. $0.38), sales $366M (+29% y/y, est. $345.1M).

MORNING BID 🔸 QXO ( $QXO) is in talks to buy Beacon Roofing Supply (BECN) for $11B ($124.35/share in cash). 🔸 Uber ( $UBER) & Lyft ( $LYFT) dominate North American ride-hailing, but Bolt aims to challenge them, per The Information. 🔸 Xpeng ( $XPEV) plans to mass-produce its modular flying car by 2026, said Chairman He Xiaopeng. 🔸 Yum China ( $YUM) appointed Adrian Ding as CFO, removing his interim title after a search following Andy Yeung’s resignation. 🔸 Franco-Nevada ( $FNV) Q4 adj. EPS $0.95 (est. $0.89), revenue $321M (+6% y/y, est. $304.44M); expects 2025 revenue to rise 25%+ with gold at $2,800/oz. Upgrades: 🔸 Grainger ( $GWW), Fastenal (FAST) → Outperform (from Market Perform) at William Blair. 🔸 Knight-Swift ( $KNX) → Neutral (from Sell) at Citigroup. Downgrade: 🔸 Sherwin-Williams ( $SHW) → Hold (from Buy) at Jefferies. 🔸 Beam Therapeutics ( $BEAM) prices 16.2M shares at $28.48 each. 🔸 DexCom ( $DXCM) gets FDA warning after inspections but sees no material impact on FY25 revenue. 🔸 Nordisk ( $NVO) reports REDEFINE 2 trial met its primary endpoint, showing significant weight loss with CagriSema in 1,206 patients over 68 weeks. 🔸 Trevi ( $TRVI) Phase 2a RIVER trial: Haduvio reduced 24-hour cough frequency by 67% (57% placebo-adjusted, p<0.0001). 🔸 Cognizant ( $CTSH) shares rose as Mantle Ridge built a $1B+ stake, seeing them as undervalued (WSJ). Upgrades: 🔸 DocuSign ( $DOCU) → Neutral (from Underweight) at JPMorgan. Deals: 🔸 NVent ( $NVT) to buy Avail’s electrical products for $975M, expects EPS boost in year one. 🔸 Perion ( $PERI) expands buyback program to $125M. 🔸 Taiwan Semi ( $TSM) Feb revenue NT$260.01B (+43% y/y, -11% m/m); Jan-Feb total NT$553.30B (+39% y/y).

作为一个股票小菜鸟，昨天做了一个我认为正确的决定，就是忍住没追高买 $NVO ,买入了 $MSTR ,至于我认为的正确是不是真的正确，让时间和市场来验证吧。

$NVO good start

$NVO (stock section) into my level ,now start scaling into pos down here for mid term

$NVO (stock section) into my level ,now start scaling into pos down for mid term

诺和诺德比较类似前段时间超微电脑，因为一个会计团队不干了，导致股价跌到20出头，最后查完啥事情没有又拉到40. 诺和诺德也是仅仅因为一个新药临床数据直接100暴跌到80，但是它的销售数据依然比礼来牛逼，市值礼来一半，盈利能力强悍，所以基本面其实并没发生啥大的变化.肯定也是折腾几天涨回去.

夜盘诺和诺德 $NVO 涨到了88，希望给个机会100就走，这个市盈率很低了，销售数据业绩各方面都比礼来好，市值是礼来一半. 回个100应该不难吧.

诺和诺德 $NVO 买了一万股买爆它，市场太傻逼了. 实际效果减重22%，安慰剂2%，预期25%， 这尼玛又不是业绩不及预期，只是药物效果不及预期，况且22%很牛逼了😂 这砸盘的不都有病么，预计价格很快被修正.

MORNING RECAP Dollar Tree ( $DLTR) Q3: ╌Adjusted EPS: $1.12 (beat by $0.04) ╌Revenue: $7.56B (beat by $120M) ╌Same-store sales growth: Dollar Tree +1.8%, Family Dollar +1.9%, Enterprise +1.8% ╌Q4 Guidance: EPS $2.10-$2.30, Revenue $8.1B-$8.3B ╌Continues strategic review of Family Dollar segment Foot Locker ( $FL) Q3: ╌Adjusted EPS: $0.33 (missed by $0.08) ╌Sales: $1.96B (missed by $60M) ╌Comp sales: +2.4% (below estimate) ╌FY25 adjusted EPS forecast lowered to $1.20-$1.30 from $1.50-$1.70 ╌FY25 comp sales growth narrowed to 1%-1.5% ╌Gross margin now expected at 28.7%-28.8% General Motors ( $GM): ╌To record over $5B in non-cash charges for China JV: ╌Restructuring: $2.6B-$2.9B ╌Reduced value: $2.7B Torrid Holdings ( $CURV) Q3: ╌EPS: ($0.01) (missed by $0.04) ╌Adj EBITDA: $19.584M (missed by $7.2M) ╌Revenue: $263.766M (missed by $22M) ╌Q4 Guidance: Sales $255M-$270M, Adj EBITDA $9M-$15M ╌FY25 Guidance: Sales $1.083B-$1.098B, Adj EBITDA $101M-$107M Volkswagen ( $VWAGY): ╌Recalls 4,616 vehicles in the US due to potential battery overheating/fire risk. Crescent Energy ( $CRGY): ╌Acquires Eagle Ford assets from Ridgemar Energy for $905M upfront, with additional oil price-based payments. Intuitive Machines ( $LUNR): ╌Offers 9.523 million shares at $10.50 each. Old Dominion ( $ODFL) November Performance: ╌LTL tons/day: -8% ╌LTL shipments/day: -6.8% ╌LTL weight/shipment: -1.2% XPO, Inc. ( $XPO) November Metrics: ╌LTL tonnage/day down 4.0% from last year. ╌Shipments/day down 4.2%. ╌Weight/shipment up by 0.2%. Goldman Sachs ( $GS): ╌CEO David Solomon sold 6,550 shares at $610.91/share. Iris Energy ( $IREN): ╌Issues $300M in convertible senior notes due 2030. Raymond James Financial Inc ( $RJF): ╌Authorizes $1.5B share repurchase. ╌Increases dividend to $0.50. Royal Bank of Canada ( $RY) Q4: ╌Adjusted EPS: C$3.07 (up from C$2.65) ╌Revenue: C$15.07B (up from C$12.69B) ╌Dividend raised by 4.2%. Eli Lilly ( $LLY) vs. Novo Nordisk ( $NVO): ╌Zepbound outperforms Wegovy with 20% vs. 14% body weight loss. Novavax ( $NVAX): ╌Sells Czech manufacturing facility to Novo Nordisk for $200M, aiming for $80M annual cost reduction. Revolution Medicines ( $RVMD): ╌Secondary offering of 14.13M shares at $46.00 each. Salesforce Inc. ( $CRM) Q3: ╌Adjusted EPS: $2.41 (vs. est. $2.44) ╌Revenue: $9.44B (vs. est. $9.348B) ╌Q4 Revenue Guidance: $9.9B-$10.1B (vs. est. $10.05B) ╌FY Revenue Guidance: Raised to $37.8B-$38.0B ╌Q4 Adj EPS Guidance: $2.57-$2.62 (vs. est. $2.65) ╌FY Adj EPS Guidance: $9.98-$10.03 (vs. est. $10.11) Box Inc. ( $BOX) Q3: ╌EPS: $0.45 (vs. est. $0.42) ╌Revenue: $275.9M (up 5% y/y, vs. est. $275.1M) ╌RPO: $1.282B, up 13% q/q ╌FY25 EPS Guidance Raised to $1.70 ╌FY25 Revenue Guidance Narrows to $1.09B Couchbase Inc. ( $BASE) Q3: ╌EPS: ($0.35) (vs. est. ($0.08)) ╌Revenue: $51.628M (vs. est. $50.78M) ╌Q4 Revenue Guidance: $52.7M-$53.5M (vs. est. $54.05M) ╌Q4 ARR: $236.5M-$239.5M Marvell Technologies ( $MRVL) Q3: ╌Adjusted EPS: $0.43 (vs. est. $0.41) ╌Revenue: $1.52B (up 6.9% y/y, vs. est. $1.45B) ╌Q4 Adjusted EPS Guidance: $0.59±$0.05 ╌Q4 Revenue Guidance: $1.8B±5% (vs. est. $1.65B) Okta Inc. ( $OKTA): ╌Q3 Adjusted EPS: $0.67 (vs. est. $0.58) ╌Revenue: $665M (vs. est. $649.7M) ╌Q4 Revenue Guidance: $667M-$669M ╌Q4 Adjusted EPS Guidance: $0.73-$0.74 ╌FY Revenue Guidance: $2.595B-$2.597B ╌FY Adjusted EPS Guidance: $2.75-$2.76 Pure Storage ( $PSTG): ╌Q3 Adjusted EPS: $0.50 (vs. est. $0.42) ╌Revenue: $831.1M (vs. est. $814.88M) ╌Q4 Revenue Guidance: $867M ╌Q4 Adjusted Operating Income: $135M NXP Semiconductors ( $NXPI) & Taiwan Semiconductor ( $TSM): ╌Discussing $8B Singapore venture expansion amid U.S.-China tech tensions.

$LLY $NVO - White House Proposes Expansion of Medicare, Medicaid Payments for Obesity Drugs -- WSJ U.S. Proposal Would Make Millions Eligible for Coverage of Weight-Loss Drugs -- WSJ Medicare Currently Pays for Limited Use of Weight-Loss Drugs -- WSJ